Predicting future heart problems in young adults with premature coronary artery disease (MAP-CHD)

Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial

This project will follow Chinese adults under 45 with premature coronary artery disease to see if clinical features and blood tests can predict future adverse heart events.

Quick facts

• Study type: Observational
• Enrollment: 5000 (estimated)
• Ages: 18 Years to 45 Years
• Sex: All
• Sponsor: China National Center for Cardiovascular Diseases (other gov)
• Locations: 1 site (Beijing)
• Trial ID: NCT07004452 on ClinicalTrials.gov

What this trial studies

MAP-CHD is an observational cohort that enrolls patients aged 18–45 with angiographically confirmed coronary artery disease and follows them for two years. Participants will have a blood draw at one year and routine outpatient or telephone follow-up at other timepoints to capture clinical outcomes. The study will combine clinical, laboratory, and phenotypic data to build a risk prediction model for adverse events and compare prognosis across disease phenotypes. No experimental treatments are given; the aim is to generate tools to stratify risk in this younger patient group.

Who should consider this trial

Good fit: Ideal candidates are Chinese adults 18–45 with at least 50% coronary stenosis on angiography who are clinically stable if enrolled after ACS or PCI and can give informed consent.

Not a fit: Patients unlikely to benefit include heart transplant recipients, those with life-limiting comorbidities (life expectancy <1 year), or individuals unable to complete follow-up.

Why it matters

Potential benefit: If successful, the model could help identify young patients at high risk of future heart problems so clinicians can tailor monitoring and preventive care.

How similar studies have performed: Existing risk models for coronary disease exist but few focus specifically on Chinese patients under 45, so this multimodal prediction approach is relatively novel for this population.

Eligibility criteria

Inclusion Criteria:

* Age 18-45 years;
* Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;
* For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;
* Voluntary participation with signed informed consent.

Exclusion Criteria:

* Heart transplant recipients;
* Severe systemic comorbidities with life expectancy \<1 year;
* Previous enrollment in other drug/device clinical trials without completing the primary endpoint observation period;
* Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).

Where this trial is running

Beijing

• FuWai Hospital — Beijing, China (RECRUITING)

Study contacts

• Study coordinator: Jingjing Xu

Conditions: Premature Coronary Heart Disease